Related Experiment Video
Updated: Jun 14, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Association of common genetic alterations with tumor recurrence in papillary thyroid cancer
Shi-Tong Yu1, Liyuan Huang1, Hui Tang2
1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background:
To comprehensively investigate the relationship between common genetic alterations and tumor recurrence in patients with papillary thyroid cancer (PTC) and evaluate whether integrating genetic status could improve the performance of the 2025 American Thyroid Association (ATA) tumor recurrence risk stratification system (RSS).
Methods:
This retrospective study included 2,056 patients (1,414 females and 642 males) with a median age of 39 years [interquartile range (IQR), 31-50 years] and a median follow-up time of 25 months (IQR, 13-35 months) who were treated for PTC at three medical centers in China between 2020 and 2024.
Results:
Tumor recurrence rates were significantly higher in patients carrying RET fusions alone or genetic alteration combination, but not in patients carrying BRAF V600E alone, RAS mutations alone, or NTRK fusions alone, than that in patients without any genetic alteration, with an HR of 2.64 (95% CI, 1.31-5.32) and 3.37 (95% CI, 1.21-9.35) after adjusted for clinicopathological factors, respectively. RET fusions or genetic alteration combination were significantly associated with increased risk of tumor recurrence in all the ATA RSS categories, with an adjusted HR of 14.02 (95% CI, 3.75-52.48) in patients with ATA RSS low or low-intermediate categories, an HR of 3.01 (95% CI, 1.51-5.99) in the intermediate-high category, and an HR of 3.75 (95% CI, 2.17-6.48) in the high category, respectively.
Conclusion:
RET fusions and genetic alteration combination are independent prognostic markers for tumor recurrence of PTC, integrating tumors' genetic status into the 2025 ATA RSS system improves the accuracy of risk stratification for PTC.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:28Graves' Disease I: Introduction
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:21Cancers Originate from Somatic Mutations in a Single Cell